康柏西普联合玻璃体切割术治疗增生性糖尿病视网膜病变的疗效分析

目的：探讨康柏西普联合玻璃体切割术治疗增生性糖尿病视网膜病变的疗效。方法：本研究选取了100例增生性糖尿病视网膜病变，年龄27~68岁，对照组（47例）单纯给予玻璃体切割术治疗，康柏西普组（53例）采用玻璃体切除术前3~6天眼内注射康博西普治疗。通过对患者术前术后6个月最佳矫正视力（BCVA），术前，术后3个月、6个月黄斑中心凹厚度，随访6个月期间并发症情况进行记录，评价康柏西普联合玻璃体切割术治疗增生性糖尿病视网膜病变的疗效。结果：术前两组 BCVA 相比，差异没有统计学意义；术后6个月，康博西普组和对照组 BCVA 均明显提高，且康博西普组 BCVA 高于对照组，与术前相比，术后3个月，6个月的黄斑中心凹厚度均明显变薄。随访6个月期间，康博西普组并发症发生率明显低于对照组。结论：康柏西普联合玻璃体切割术治疗增生性糖尿病视网膜病变可有效改善视力，减轻黄斑水肿症状，术后并发症较少。

Analysis of the efficacy of the conbercept combined with vitrectomy in the treatment of proliferative diabetic retinopathy

Objective Discuss the efficacy of the conbercept combined with vitrectomy in the treatment of proliferative diabetic retinopathy. Methods 100 patients with proliferative diabetic retinopathy were selected, 27~68 years old, the control group (47 cases) was only given vitrectomy, the conbercept group (53 cases) was given conbercept combined with vitrectomy. The efficacy of the conbercept combined with vitrectomy in the treatment of proliferative diabetic retinopathy was evaluated by BCVA, foveal thickness, the complication rate. Results There were no statistical significance on BCVA between two groups. After 6 months surgery, the BCVA in the conbercept group and control group was increased apparently. And the BCVA in the conbercept group was higher than that of the control group. Compared with the value before surgery, the Compare with the values before surgery, the foveal thickness was thinner after 3 months and 6 months surgery. During the follow-up period of 6 months, the complication rate in the conbercept group was apparently lower than than of the control group. Conclusion The conbercept combined with vitrectomy in the treatment of proliferative diabetic retinopathy could improve eyesight effectively, reduce the symptoms of macular edema and postoperative complications.